Multiple Sclerosis and Neuroimmunology Clinical Trials
Project BIG: The Stanford Brain Immune Gut Research Initiative
PI: Jeffrey Dunn, MD
Research Coordinator: Julia Sumera, jsumera@stanford.edu
Status: Enrolling
A Multicenter Randomized Controlled Trial of Best Available Therapy versus Autologous Hematopoietic Stem Cell Transplant for Treatment-Resistant Relapsing Multiple Sclerosis
NCT04047628
PI: Jeffrey Dunn, MD
Research Coordinator: Crystal Ton-Nu, ctonnu@stanford.edu
Status: Enrolling
A Multiple-center, Non-Randomized, Open-Label, Adaptive, Single Ascending Dose Phase I Study to Investigate the Safety, Tolerability, Immunogenicity, Pharmacokinetics, and Pharmacodynamics of RO7121932 Following Intravenous Administration in Patients with Multiple Sclerosis
NCT05704361
PI: Christopher Lock, MD
Research Coordinator: Safiyyah Bachar, sbachar@stanford.edu
Status: Enrolling
High Dimensional Analysis of Immune Subsets with Mass Cytometry and Multiparameter Flow Cytometry in Patients with Secondary Progressive Multiple Sclerosis Treated with Siponimod
PI: Lawrence Steinman MD
Research Coordinator: Julia Sumera, jsumera@stanford.edu
Status: Enrolling
Ozanimod (Zeposia) in Multiple Sclerosis and Ulcerative Colitis: High Dimensional Immunometabolomic Analysis of Immune Cell Subsets with CyToF, CITE-seq, and Multiparameter Flow Cytometry In Treated Individuals Compared with Baseline.
PI: Lawrence Steinman MD
Research Coordinator: Julia Sumera, jsumera@stanford.edu
Status: Enrolling
A Phase III Multicenter, Randomized, Double-Blind, Double-Dummy, Parallel-Group Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared with Teriflunomide in Adult Patients with Relapsing Multiple Sclerosis (GN42272)
NCT04586023
PI: Lucas Kipp MD
Research Coordinator: Julia Sumera, jsumera@stanford.edu
Status: Enrolling
CorEvitas SPHERES (Synergy of Prospective Health & Experimental Research for Emerging Solutions) Registry for Neuromyelitis Optica Spectrum Disorder (NMOSD)
NCT04886492
PI: May Han, MD
Research Coordinator: Tara Sarkar, tarats@stanford.edu
Status: Enrolling
A Randomized, Double-blind, Placebo-Controlled, Multicenter, Phase 3, Pivotal Study with an Open-Label Extension Period to Evaluate the Efficacy and Safety of Rozanlixizumab in Adult Participants with Myelin Oligodentrocyte Glycoprotein (MOG) antibody-associated disease (MOG-AD)
NCT05063162
PI: May Han, MD
Research Coordinator: Tara Sarkar, tarats@stanford.edu
Status: Enrolling
Retinal Biomarkers of Inflammation and Degeneration in Multiple Sclerosis
PI: Heather Moss, MD
Research Coordinator: Tara Sarkar, tarats@stanford.edu
Status: Enrolling